Timing
Purchase and sale flow
PurchasesSales
Stock, pipeline and biotech catalyst intelligence
Reported ownership activity
Activity signal
Reported sales exceed purchases by $8.9MOption exercises, awards, and grants are separated from open-market direction.Timing
Composition
Concentration
Company profile
Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases. The company's lead product candidate is QTORIN rapamycin, a novel, 3.9% anhydrous topical gel that is in Phase 3 clinical trial for the treatment of microcystic lymphatic malformations, as well as in Phase 2 clinical trial to treat cutaneous venous malformations. It also develops QTORIN rapamycin for the treatment of angiokeratomas and other mTOR-driven skin diseases; and QTORIN pitavastatin for the treatment of disseminated superficial actinic porokeratosis. The company is based in Wayne, Pennsylvania.
Company profile supplied by Yahoo Finance. Catalyst dates can change and should be confirmed against the linked primary source.
Page updated Aug 21, 2026 · Yahoo quotes cached for one minute; reference data may be used when a live field is unavailable.
| Insider trading | Relationship | Date | Transaction | Cost | Shares | Value | Shares total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Goin Kathleen | Chief Operating Officer | Aug 19 '26 | Option Exercise | $8.11 | 4,302 | $34,883 | 4,302 | Aug 20 04:05 PM |
| Goin Kathleen | Chief Operating Officer | Aug 19 '26 | Sale | $152.21 | 4,302 | $654,791 | 0 | Aug 20 04:05 PM |
| Goin Kathleen | Officer | Aug 19 '26 | Proposed Sale | $150.42 | 4,302 | $647,107 | — | Aug 19 04:56 PM |
Transactions may include sales, purchases, grants, and option exercises. Directional charts count only purchases and sales; follow the Form 4 link to verify the original SEC filing.